According to the Kaplan–Meier analysis, patients with high levels of sPD-L1 in serum had significantly shorter cancer-specific survival than those with low levels of sPD-L1: 18.5 months versus 40.9 months (p = 0.002) (Figure 5). This evidence concerns the gene SPDL1 and cancer.